Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study

作者：Elizabeth D. Lowenthal, Jennifer Chapman, Rachel Ohrenschall, Katherine Calabrese, Kristin Baltrusaitis, Barbara Heckman, Dwight E. Yin, Allison L. Agwu, Conn Harrington, Rodica M Van Solingen-Ristea, Cynthia McCoig, Adeola Adeyeye, J. Kneebone, Vasiliki Chounta, Christiana Smith-Anderson, Andrés Camacho-González, Jessica D'Angelo, Allison Bearden, Herta Crauwels, Jenny Huang, Sarah Buisson, Ryan O. Milligan, S. M. Ward, Carolyn Bolton‐Moore, Aditya H. Gaur, Brookie M. Best, Edmund V. Capparelli, Sherika Hanley, Sisinyana Ruth Mathiba, Megeshinee Naidoo, Pradthana Ounchanum, Faeezah Patel, Mary E. Paul, Ellen Townley, Kati Vandermeulen, Kyle Whitson, Sara Zabih · 发表于：The Lancet HIV · 年份：2024 · DOI：10.1016/s2352-3018(23)00301-6 · 被引用次数：26 · 研究领域：HIV/AIDS drug development and treatment、HIV/AIDS Research and Interventions、HIV-related health complications and treatments